AP957A - Novel stable liquid paracetamol compositions, and method for preparing same. - Google Patents

Novel stable liquid paracetamol compositions, and method for preparing same. Download PDF

Info

Publication number
AP957A
AP957A APAP/P/1998/001223A AP9801223A AP957A AP 957 A AP957 A AP 957A AP 9801223 A AP9801223 A AP 9801223A AP 957 A AP957 A AP 957A
Authority
AP
ARIPO
Prior art keywords
paracetamol
stable
liquid formulations
formulations according
solution
Prior art date
Application number
APAP/P/1998/001223A
Other versions
AP9801223A0 (en
Inventor
Francois Dietlin
Daniéle Fredj
Original Assignee
Scr Pharmatop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP957(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scr Pharmatop filed Critical Scr Pharmatop
Publication of AP9801223A0 publication Critical patent/AP9801223A0/en
Application granted granted Critical
Publication of AP957A publication Critical patent/AP957A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Novel stable paracetamol compositions for use in therapeutic chemistry and specifically galenic pharmacy are disclosed. The compositions contain a solution of paracetamol in an aqueous solvent combined with a buffer having a pH of 4 to 8, and a free radical capturing agent. A water-insoluble inert gas is carefully bubbled through the aqueous solvent to remove oxygen from the medium. Said compositions may also be combined with a centrally or peripherally acting analgesic agent, and are provided as injectable compositions for relieving pain.

Description

NOVEL STABLE PARACETAMOL-BASED LIQUID FORMULATIONS AND A METHOD FOR PREPARING THE SAME
FIELD OF THE INVENTION
The present invention relates to novel stable, liquid, analgesic formulations, containing paracetamol as main active ingredient, either in combination or not, with an analgesic derivative.
io DISCUSSION OF THE PRIOR ART
It has been known for many years and notably from a paper of FAIRBROTHER J.E. entitled : Acetaminophen, published in Analytical Profiles of Drug Substances (1974), volume 3, pp. 1 - 109, that paracetamol in the presence of moisture, and all the more in aqueous solution, may be hydrolysed is to yield p-aminophenol, which compound may itself be broken down into quinone-imine. The rate of decomposition of paracetamol is enhanced as the temperature is increased and upon exposure to light.
In addition, the instability of paracetamol in aqueous solution as a function of the solution’s pH has been extensively described. Thus, according to a paper entitled Stability of aqueous solutions of N-acetyl-p-aminophenol” (KOSHY K.T. and LACH J.I.J. Pharm. Sci., 50 (1961), pp. 113 - 118), paracetamol in aqueous solution is unstable, a fact which primarily correlates with hydrolysis both in acidic and basic environment. This breakdown process is minimal at a pH close to 6, the half-life of the product thus degraded namely being as high as 21.8 years at 25°C.
According to Arrhenius law and knowing the specific reaction constant as determined by these authors, the time needed to observe a 5% decrease in paracetamol concentration of an aqueous solution stored at 25°C at the optimal pH has been predicted to be 19 months. Besides hydrolysis, the paracetamol molecule separately undergoes another kind of decomposition
AP/F,' 9 8 / 0 1 2 2 3
AP 00957 that involves formation of a quinone-imine that may readily polymerize with generation of nitrogen-containing polymers.
These polymers and in particular those stemming from N-acetyl-pbenzoquinone-imine have been further described as being the toxic metabolite of paracetamol, which is endowed notably with cytotoxic and hemolytic effect.
The decomposition of this metabolite in aqueous medium is still more complex and gives rise to p-benzoquinone and hydroquinone (D. DAHLIN, J. Med.
Chem., 25 (1982), 885-886).
In the current state of the art and in view of the quality control io requirements specific to pharmaceutical practice regulations, the stability of paracetamol in aqueous solutions is thus insufficient and does not allow the formulation of liquid pharmaceutical compositions for injection. As a result, the successful preparation of liquid phamaceutical formulations for parenteral administration, based on paracetamol, has not been achieved.
A number of trials has been undertaken to slow down the decomposition of paracetamol in aqueous solution. Thus, in a paper entitled ; Stabilization by ethylenediamine tetraacetic acid of amide and other groups in drug compound, (FOGG Q.G. and SUMMAN, A.M., J. Clin. Pharm. Ther., 17 :
(1992), 107 - 109), it is stated that a 0.1% aqueous solution of paracetamol has <X a p-aminophen content resulting from hydrolysis of paracetamol, approximating 19,8% of the initial concentration of paracetamol, as observed after storage in the dark during 120 days. Addition of EDTA at a rate de 0.0075% brings down the decomposition rate to 7%. On the other hand, distilling an alkaline solution of paracetamol results in an ammonia concentration of 14%, in presence or not of 1000 ppm of ascorbic acid. Owing to its properties, ascorbic acid is Indeed quite adapted to such stabilization. However, upon exposure to bright light, a paracetamol solution containing 1000 ppm of ascorbic acid does after all generate ammonia with a yield of 98%. In contrast, addition of EDTA (0.0075%) to such a solution cuts down decomposition rate, with an ammonia yield not higher than 14%.
98/01223
AP 00957
Despite of such efforts, it has not been possible to prepare aqueous liquid solutions of paracetamol, in particular solutions for injection, having a guaranteed stability.
SUMMARY OF THE INVENTION
The present invention is aimed at solving the above stated problem in an appropriate manner. It is directed to stable pharmaceutical compositions of paracetamol in an aqueous solvent having added thereto a free radical antagonist. The aqueous solvent may be water or else aqueous mixtures io containing water and a polyhydric compound such as polyethylene-glycol (PEG) 300, 400, 1000, 1540, 4000 or 8000, propylene glycol or tetraglycol. A water-soluble alcanol such as for example ethanol may also be used.
DETAILED DESCRIPTION OF THE INVENTION is Stability of the aqueous solutions mentioned above does not solely depend on the choice of a given carrier. It also depends on other variables, such as careful adjustment of pH, removal of oxygen dissolved in the carrier and addition of a free radical antagonist or a free radical scavenger.
Removal of dissolved oxygen is readily accomplished by bubbling an inert gas and preferably by bubbling nitrogen.
The appropriate free radical antagonist is chosen among the derivatives of ascorbic acid, those derivatives bearing at least a thiol functional group and straight chain or cyclic polyhydric compounds.
Preferred ascorbic acid derivatives are D- or L-ascorbic acid, an alkali metal ascorbate, an alkaline earth metal ascorbate or even still an aqueous medium-soluble ascorbic acid ester.
Free radical scavengers, bearing a thiol functional group may be an organic compound substituted by one or more thiol functional groups, of the aliphatic series such as cystein, acetylcystein, thioglycoilic acid and salts thereof, thioiactic acid and salts thereof, dithiothreitol, reduced glutathion, thiourea, thioglyceroi, methionine and mercaptoethane sulfonic acid.
AP/P/ 9 8 / 0 1 2 2 3
AP 00957
The polyol used as a free radical scavenger is preferably a straight chain or a cyclic, polyhydroxy alcohol such as mannitol, sorbitol, inositol, isosorbide, glycerol, glucose and propylene-glycols.
Among free radical scavengers required pour stabilizing paracetamol, 5 the ascorbic acid derivative currently preferred is sodium ascorbate. Preferred thiol functional group substitued derivatives are cystein, reduced-state glutathion, N-acetylcystein and mercaptoethane sulfonic acid.
It may appear as convenient to combine several free radical scavengers as far as they are water-soluble and mutually compatible, io Especially convenient free radical scavengers are mannitol, glucose, sorbitol or even glycerol. These may be readily combined.
It may appear as convenient to add to the preparation one or a number of complexing agents to improve stability of the molecule since the active ingredient is sensitive to the presence of trace metals that eventually speed up is its decay.
Complexing agents are exemplified by nitrilotriacetic acid, ethylene diamino tetraacetic acid, ethylene diamino N, N’-diacetic-N, N’-dipropionic acid, ethylene diamino tetraphosphonic acid, 2, 2’-(ethylene diamino)dibutyric acid, or ethylene-glycol bis(diaminoethyl ether) N, N, Ν’, N’-tetraacetic acid and sodium or calcium salts thereof.
The complexing agent also acts to complex bivalent ions (copper, zinc, cadmium) that may be present and that have a negative influence of the aging of the formulation throughout storage.
The gas that is bubbled into the solution to drive out oxygen, may be 25 nitrogen or carbon dioxide or still an inert gas. Nitrogen is favoured.
Isotonicity of the preparation may be achieved by adding an appropriate quantity of sodium chloride, glucose, levulose or postassium chloride, or calcium chloride, or calcium gluconoglucoheptonate, or mixtures thereof. The preferred isotonizing agent is sodium chloride.
The buffer used is a buffer compatible with parenteral administration in humans, the pH of which may be adjusted between 4 and 8. Preferred buffers
AP 00957 are based on alkali metal ou alkaline earth metal acetates or phosphates. A more preferred buffer is sodium acetate/hydrogeno phosphate adjusted to the required pH with hydrochloric acid or sodium hydroxide. The concentration of such a buffer may be comprised betwenn 0.1 and 10 mg/ml. The preferred concentration is confined in the range of 0.25 to 5 mg/ml.
On the other hand, preparations for injection have to be sterile and should lend themselves to heat treatment sterilization. It is known that in certain conditions, antioxidants such as glutathion are broken down [FI ALAI RE A. et al., J. Pharm. Biomed, Anal., vol. 10, N° 6, pp. 457 - 460 (1992)]. The io breakdown of reduced glutathion during heat treatment sterilization ranges from 40 to 77% depending on the selected temperature conditions. During such sterilization procedures, it is convenient to employ means capable of preserving the integrity of these antioxidants. Addition of complexing agents to aqueous solutions inhibits thermal decomposition of thiol derivatives, such as glutathion.
Liquid pharmaceutical compositions according to the invention are preferably compositions intended for injection. The paracetamol content of the solution may range from 2 mg/ml to 50 mg/ml in case of so-called dilute solutions, i.e. that can be directly infused by intravenous route and from 60 mg/ml to 350 mg/ml where so-called concentrated solutions are considered,
i.e. either intended for direct injection by intraveinous or intramuscular route, or intended to be diluted prior to slow infusion administration. The preferred concentrations are comprised between 5 and 20 mg/ml for dilute solutions and between 100 and 250 mg/ml for concentrated solutions.
Pharmaceutical compositions according to the invention may further contain another active ingredient that enhances the specific effet of paracetamol.
In particular, the pharmaceutical compositions according to the invention may contain a CNS-acting analgesic such as for example a morphinic analgesic.
ΑΡ/Γ; 9 8/01223
AP 00957 *
The morphinic analgesic is selected among the morphinic derivatives of natural, semi-synthetic or synthetic origin and piperidine derivatives selected from the following list, which is no way intended to be exhaustive: buprenorphine, ciramadol, codeine, dextromoramide, dextropropoxyphene, hydrocodone, hydromorphone, ketobemidone, levomethadone, levorphanol, meptazinol, methadone, morphine, nalbuphine, nicomorphine, dizocine, diamorphine, dihydrocodeine, dipipanone, methorphane, dextromethorphane.
Preferred morphinic derivatives are codeine sulfate or morphine hydrochloride.
io The codeine or codeine derivative concentration, expressed in terms of codeine base, is comprised between 0.2% and 25% in relation to the paracetamol content. The preferred codeine derivative is codeine sulfate. The concentration thereof is set between 0.5 and 15% in relation to the paracetamol content
The morphine or morphine derivative concentration, expressed in terms of morphine base, is comprised between 0.05 and 5% in relation to the paracetamol content. The preferred morphine derivative is morphine hydrochloride the concentration of which is preferably set between 0.5 and 15% in relation to paracetamol content.
The compositions according to the invention may further have added thereto an anti-inflammatory agent such as of the of AINS type and in particular a phenylacetic acid compound. Such agents are exemplified by ketoprofen, flurbiprofen, tiaprofenic acid, niflumic acid, diclofenac or naproxen.
Compositions according to the invention may in addition incorporate an antiemetic either a CNS-acting neuroleptic such as haloperidol or chlorpromazine or metopimazine or of the gastrokinetic-mediated type such as metochiopramide or domperidone or even a serotoninergic agent.
Compositions in accordance with the invention may further incorporate an anti-epileptic drug such as sodium valproate, clonazepam, carbamazepine or phenytoin.
AP/F/ 9 8 / 0 1 2 2 3
AP 00957
It may also be possible to combine paracetamol with a corticosteroid such as for example prednisone, prednisolone, methyl prednisone, dexamethasone, betametasone or an ester thereof.
Paracetamol can further be combined with a tricyclic antidepressant 5 such as amitriptiline, imipramine, clomipramine.
Anti-inflammatory agents may be included in concentrations ranging from 0.100 g to 0.500 g per 1000 ml of formulated product.
In case of concentrated solutions
The water content expressed in percentage is preferably in exces of 5% io of the total volume and more preferably comprised between 10 and 65%.
The quantity of propylene glycol formulated in percentage is preferably in excess of 5% and more preferably comprised between 20 and 50%.
The PEG used is preferably PEG 300, PEG 400, PEG 1000, Peg 1540 or PEG 4000. Concentrations used are comprised between 10 and 60% in is weight. PEG 300 and PEG 400 are further preferred. Preferred concentrations range from 20 to 60%.
Ethanol concentrations range from 0 to 30% of total volume and preferably range from 0 to 20%.
Tetraglycol concentrations used do not exceed 15% to allow for 20 maximal quantities that can daily be received by parenteral administration viz.
0.7 ml/kg of body weight.
Glycerol concentration varies from 0.5 to 5% as a function of the viscosity of the medium suitable for use depending on the administration route.
In case of dilute solutions
The quantity of water used given in percentage is preferably in excess of 20% ofthe total volume and preferably is comprised between 25 and 100%.
The quantity of propylene-glycol employed given in percentage is preferably comprised between 0 and 10%.
The PEG used is preferably PEG 300, PEG 400, or PEG 4000 with 30 PEG 4000 being most preferred. Preferred concentrations range from 0 to
AP/P/ 9 8 / 0 1 2 2 3
AP 00957
10%. Tetraglycol concentrations used do not exceed 5%. In preference, they are comprised between 0 and 4%.
The ascorbic acid or ascorbic acid derivative concentration which is used, is preferably more than 0.05 mg/ml and more desirably, comprised between 0.15 mg/ml and 5 mg/ml. Higher quantities may indeed be used, without exceeding the solubility limits. Higher ascorbic acid or ascorbic acid derivative concentration are administered to human beings for prophylactic or therapeutic purposes.
Thiol derivative concentration is comprised between 0.001% and 30% io and more desirably, comprised between 0.005% and 0.5% for dilute solutions, and between 0.1 % and 20% for concentrated solutions.
The pH of the solution is desirably adjusted taking into consideration the optimal stability of paracetamol in aqueous solution, i.e. at a pH around 6,0.
The thus prepared composition may be packaged in glass sealed vials, or in stoppered glass vials or in bottles made of a polymer material such as polyethylene, or in soft material bags made from polyethylene, polyvinyl chloride or polypropylene.
The composition may be sterilized by heat treatment, for example at
121 °C during 20 minutes or else by sterile filtration.
Currently preferred compositions in accordance with the invention have the following ingredients :
AP/P/ 9 8 / 0 1 2 2 3
Concentrated solutions
AP 00957
Ingredient Injection solution of paracetamol alone (per ml) Injection solution of paracetamol associated to a morphinic compound (per ml)
codein morphine
paracetamol 0.160 g 0.160 g 0.160 g
codein sulfate.3H2O - 0.0036 g -
Morphine hydrochloride.3H2O 0.00037
Propylene-glycol 0.270 ml 0.270 ml 0.270 ml
PEG 400 0.360 ml 0.360 ml 0.360 ml
Sodium acetate 0.002 g 0.002 g 0.002 g
Reduced glutathion 0.002 g 0.002 g 0.002 g
Hydrochloric acid 1 N q.s. pH 6.0* q.s. pH 6.0* q.s. pH 6.0*
Water for injection q.s. 1000 ml q.s. 1000 ml q.s. 1000 ml
Nitrogen q.s.f. bubbling q.s.f. bubbling q.s.f. bubbling
* The pH specified above is the actual pH that has been measured by a pH-meter after obtaining a 5 fold dilution of the solution with distilled water. It will be noted that the apparent pH of the pure solution is different.
Using this solution composed of a solvent mixture constituted by 30% of propylene-glycol, by 40% of polyethylene-glycol 400 and by 30% of water (solution n° 20), it is possible to dissolve about 200 mg/ml of paracetamol at
20°C. Choosing a concentration of 160 mg/ml allows one to be sure that no io recristallization will occur, notably at low temperatures. In such situations, a volume of 6,25 ml of said solution contains 1000 mg of paracetamol.
AP/P/ 9 8 / 0 1 2 2 3
Dilute solutions
AP 00957
Ingredient Injection solution of paracetamol alone (per ml) solution of paracetamol associated to codein (per ml)
Such morphinic compound is codein Such morphinic compound is morphine
paracetamol 0.0125 g 0.125 g 0.125 g
codein sulfate.3H2O - 0.00018 g -
Morphine hydrochloride.3H2O 0.000019 g
Mannitol 0.025 g 0.025 g 0.025 g
Sodium hydrogen phosphate dihydrate 0.0025 g 0.00025 g 0.00025 g
Sodium chloride 0.002 g 0.002 g 0.002 g
Disodium ethylene diamino tetraacetate 0.0001 g 0.0001 g 0.0001 g
Hydrochloric acid or sodium hydroxide q.s. pH 5.5 q.s. pH 5.5 q.s. pH 5.5
Water for injection , q.s.f. 1000 ml q.s. f. 1000 ml q.s. f. 1000 ml
Nitrogen q.s. f. bubbling q.s. f. bubbling q.s. f. bubbling
AP/P/ 9 8 / 0 1 2 2 3
The compositions according to the invention find therapeutic applications as pain relief drugs. For moderate pain, the solutions merely contain paracetamol. For acute pain, the solutions further contain a morphinic analgesic. Furthermore, the paracetamol solutions exert antipyretic activity.
The following examples are given by way of illustration and not by limitation.
EXAMPLE I io Determination of the optimal solvent mixture
1.1 Concentrated solutions
AP 00957
Increasing quantities of paracetamol were introduced in the solvent mixtures. The dissolution rate of paracetamol increases with rise in temperature, so that the solubility tests in the individual media were run by heating the solvent mixture to 60°C. Apres dissolution was judged complete, the solutions were stored for 72 hours either at 25°C or 4°C.
The solubility values are listed in the following table :
Test n° Water (ml) Propylene- glycol (ml) PEG 400 (ml) Ethanol Tetraglycol (ml) Solubility at +4°C (mg/ml) Solubility at +25°C (mg/ml)
1 0.3 0.4 0.3 - - 110 130
2 0.4 0.3 0.3 - - 110 130
3 0.15 0.3 0.4 - 0.15 190 230
4 0.5 - 0.5 - - 110 150
5 0.4 0.3 0.2 0.1 - <110 120
6 0.5 0.3 0.1 0.1 - < 100 130
7 0.4 0.4 0.1 0.1 - < 100 150
8 0.5 0.3 0.2 - - < 100 120
9 0.6 0.3 0.2 - - < 100 < 100
10 0.5 0.4 0.1 - - < 100 < 100
11 0.55 0.3 0.05 0.1 - < 100 < 100
12 0.45 0.4 0.05 0.1 - < 100 120
13 0.65 0.3 0.05 - - < 100 < 100
14 0.55 0.3 0.05 - - < 100 < 100
15 0.4 0.4 0.2 - - < 100 < 150
16 0.45 0.45 0.1 - - < 100 < 110
17 0.4 0.2 0.4 - - 160 200
18 0.5 0.2 0.3 - - 160 160
19 0.5 0.1 0.3 - - 100 190
20 0.3 0.3 0.4 - - 190 200
21 0.3 0.2 0.35 - 0.15 160 210
22 0.25 0.25 0.35 - 0.15 170 220
AP/P/ 9 8 / 0 1 2 2 3
AP 00957
The solubility values of the solvent mixtures do not increase in a consistent manner with increasing temperature. Solubility is not enhanced if ethanol is added.
In addition, due to oversaturation phenomena which are observed in 5 such solutions, notably in media containing PEG, a delayed recristallization was noted subsequent to cooling. In these conditions, the solutions under study were kept for 14 days at 20°C, then there was added, to the solutions displaying no cristals following this time interval, a paracetamol germ cristal in order to elicit cristal I izati on of potentially oversaturated solutions. Finally, it was io found that solutions n° 20 and n° 3 have the highest solubility with respect to I paracetamol, which threshold was comprised between 160 mg/ml and 170 mg/ml depending on temperature.
1.2 Dilute solutions is Paracetamol in quantities well exceeding the solubility threshold was introduced in the solvent mixtures previously warmed to 30°C. After stirring and cooling at 20°C, the solutions were filtered. The paracetamol content of these solutions was determined by reading the absorbance at 240 nm of a 1:200 dilution of the filtrate.
The results are recorded in the following tables.
AP/P/ 9 8 / 0 1 2 2 3
AP 00957
Type of solution (unless otherwise stated, the main solvent is distilled water) concentration of paracetamol (mg/50 ml)
Water 720
5% Glucose 710
4.82% levulose 730
7% mannitol 680
5% sorbitol 685
0.9% sodium chloride 615
10% Calcium gluconoglucoheptonate 670
Lestradet’s solution (5% glucose, 0.2% sodium chloride, 0,15% potassium chloride, 1.1% calcium gluconoglucoheptonate) 730
Ringer’s solution (0.7% sodium chloride, 0.1% potassium chloride, 0.1% sodium chloride) 730
Ringer’s solution- Phosphate (0.7% sodium chloride, 0.182% monopotassium phosphate, 0.182% calcium chloride) 710
Ringer’s solution-acetate (0.7% sodium chloride, 0.131% potassium acetate, 0.013% calcium chloride) 715
Urea 0.3 M 725
AP/P/ 9 8 / 0 1 2 2 3
Type of solution (the following solutions were prepared in Ringer’s solution) concentration of paracetamol (mg/50 ml)
Pure Ringer’s solution 735
4.0% PEG 4000 + 1.0% propylene- glycol + 0.5% ethanol 905
4.0% PEG 4000 + 1.0% propylene- glycol + 1.0% ethanol 905
4.0% PEG 4000 + 1.0% propylene- glycol + 2.0% ethanol 930
AP 00957
Type of solution (the following solutions were prepared in 0,9% sodium chloride solution) concentration of paracetamol (mg/50 ml)
0.9% sodium chloride 615
+ 0.6% tetraglycol 640
+ 1.2% tetraglycol 680
+ 3.0% tetraglycol 720
1.0% PEG 4000 630
1.0% PEG 4000 + 0.6% tetraglycol 660
1.0% PEG 4000 + 1.2% tetraglycol 710
3.0% PEG 4000 + 2.0% tetraglycol 950
Paracetamol solubility is increased by the presence of PEG.
Solubilities of paracetamol in mixtures of PEG 4000 and 0.9% sodium chloride solutions were determined in distilled water, at concentrations ranging 5 from 0 to 7%, as a function of temperature.
The results are given in the following table :
Solvent volume (ml) required to dissolve 1000 mg of paracetamol as a function of temperature
PEG 4000 concentration (%/vol.) in 0.9% sodium chloride solution 4°C 17°C 22°C 30°C 42°C
0% 130 92 80 65 42
1% 99 78 67 63 47
2% 91 72 63 59 45
3% 80 64 56 54 41
4% 82 62 57 49 36
5% 79 59 51 46 34
7% 78 61 48 42 30
AP/P/ 9 8 / 0 1 2 2 3
AP 00957
4.1 Concentrated solution
Quantity
Ingredient Solution without nitrogen bubbling solution subjected to nitrogen bubbling
Paracetamol 0.160 g 0.160 g
Propylene-glycol 0.270 ml 0.270 ml
PEG 400 0.360 ml 0.360 ml
Sodium hydroxide or HCI 1N q.s. pH 6.0 q.s. pH 6.0 .
Nitrogen none q.s. f. purging and filling
Water for injection q.s. f. 1000 ml q.s. f. 1000 ml
Solution 20 containing paracetamol in a quantity of 160 mg/ml, adjusted 5 to pH 6,0 by sodium hydroxide or hydrochloric acid 1 N, was either subjected or not subjected to nitrogen gas bubbling. Tightly stoppered and capped vials packed by dispensing 10 ml of such solutions under nitrogen atmosphere or air, were sterilized by autoclaving at 121 °C during 20 minutes. The percentage of secondary peaks was then measured by liquid chromatography with respect io to the main peak of paracetamol, as well as was the pink color strength by reading the solution absorbance by absorption spectrophotometry at peak absorbance wavelength, that is 500 nm.
Results
AP/P/ 9 8 / 0 1 2 2 3
Solution tested Secondary peaks in % of main peak of paracetamol absorbance of the solution at 500 nm
Autoclaved solution packed without nitrogen 0.054 0.08
Autoclaved solution packed under nitrogen 0.036 0.03
AP 00957
It is therefore seen that the difference in color of the solution packed under nitrogen is very striking.
In order to check if 0% and 1% PEG-paracetamol solutions remain clear under cold storage, the following solutions were prepared :
Ingredient Solution without PEG Solution with PEG added
Paracetamol 19 ig
PEG 4000 - 1 g
0.9% Sodium chloride solution in water for injection q.s. 125 ml q.s. 100 ml
After storage of these solutions at 4°C during 10 days, none of the vials tested showed cristallization. Presence of PEG is therefore not mandatory if the solutions are to remain clear throughout the time interval studied.
io
EXAMPLE II
TESTS CONDUCTED FOR CHARACTERIZING PARACETAMOL
BREAKDOWN IN SOLUTION is 2.1 Demonstrating paracetamol instability in solution
A paracetamol solution in water or in solution n° 20 shows rapidly a pink color upon exposure to light or storage at high temperature. At 50°C, color development occurs in 2 weaks time. Appearance of such color tinge correlates with an increase in solution absorbance at a peak absorbance wavelength of 500 nm. According to the paper of Fairbrother mentioned above, exposure of paracetamol to moisture can result in hydrolysis with formation of para-aminophenol, followed by oxydation, with appearance of a pink color, typical of the production of quinoneimine.
AP/P/ 9 8 / 0 1 2 2 3
2.2 Identifying the breakdown products of paracetamol
AP 00957
In aqueous or partially aqueous solutions, p-aminophenol is not detected during storage. Rapid production of colored products having a pink tinge is noted, the reaction rate being a function of temperature and light. In course of time, such derivatives are increasingly dark and evolutes to brown color.
All occurs as if, in contrast to what has been reported in the litterature, the breakdown of paracetamol first involves an oxydative process followed by hydrolysis. According to this theory, paracetamol may react with an oxidant present in solution, for example oxygen dissolved in the aqueous layer. This io mechanism may involve the production of free radicals resulting in molecular coupling, a fact that may account for the production of colored derivatives evoluting in color from pink to brown.
2.3 Tests for demonstrating inhibition of free radical production 15 A typical reaction involving the production of free radicals involves adding a 30% aqueous solution of hydrogen peroxide and a copper pentahydrate solution at a concentration of 62.5 mg/ml, to a 1.25% aqueous solution of paracetamol. In a matter of minutes, there develops a color reaction resulting in a color shift from yellow to dark brown. The color intensity observed decreases if free radical scavengers or glycerol are prior added to the paracetamol solution. Color intensity is a function of type of the type of free radical scavenger added, in the following decreasing order as judged by color intensity :
Paracetamol alone > paracetamol + N-acety Icy stein > paracetamol + cystein > paracetamol + sorbitol > paracetamol + mannitol > paracetamol + glycerol.
EXAMPLE III
Stabilizing paracetamol solution by selecting the pH that allows maximal stability
3.1 Concentrated solution
AP/P/ 9 8 / 0 1 2 2 3
AP 00957
Solution tested
Ingredient Quantity
Paracetamol 0.160 g
Propylene-glycol 0.270 ml
PEG 400 0.360 ml
Sodium hydroxide 1N or Hydrochloric acid 1N q.s.f. pH 7.0 - 8.0 - 9.0 - 9.5 -10.0 corresponding to actual pH : pH 5.8 - 6.7 - 7.1 - 7.5 - 8.0 - 8.5
Nitrogen q.s.f. purging and filling
Water for injection q.s. 1000 ml
Solution 20 containing paracetamol in a concentration of 160 mg/ml was adjusted to different pH’s : the apparent pH is given in comparison to actual pH (between parenthesis) after a 5 fold-dilution : 7,0 (5,8) - 8,0 (8,7) 8,5 (7,1) - 9,0 (7,5) - 9,5 (8,0) - 10.0 (8,5) using a sodium hydroxide or normal hydrochloric acid solution. Vials that had been filled under nitrogen atmosphere by dispensing 10 ml of such solutions, tightly stoppered and capped, were io sterilized by autoclaving at 121 °C for 20 minutes, and then in every case exposed, either to a temperature of 105°C in the dark for 72 hours, or to a radiation of an actinic light at 5000°K and 25°C during 264 hours.
Results
After autoclaving, only the solution adjusted to pH 10 shows a pink tinge. After storage at 105°C for 72 hours, absorbance at 500 nm as well as the concencentration of breakdown products of paracetamol were minimal in the pH range from 7,5 to 9,5. Upon storage in the presence of light, the color strength is enhanced as the pH is increased. Color development is extremely weak at pH 7,0 (actual pH 5,8). Neither the paracetamol content, nor the beakdown products are affected by pH.
3.2 Diluted solution
AP/P/ 9 8 / 0 1 2 2 3
AP 00957
Solution tested
Ingredient Quantity
Paracetamol 0.008 g
Sodium chloride 0.0067 g
Disodium phosphate dihydrate 0.0012 g
5% Citric acid q.s.f. pH 5.0-6.0-7.0
Nitrogen q.s.f. bubbling and filling
Water for injection q.s.f. 1000 ml
The aqueous solution diluted and buffered having a paracetamol 5 content of 8 mg/ml was adjusted to different pH values : pH 5,0 - 7,0 using a citric acid solution.
Vials that had been packed under nitrogen atmosphere by dispensing 10 ml of such solutions, were tightly stoppered and capped, sterilized by autoclaving at 121°C for 20 minutes, and then in every case exposed to 70°C io in the dark during 231 hours.
Results
Following autoclaving, only the solution adjusted to pH 7 shows a pink color. After storage, this same solution displays the brightest pink color. At pH i 6,0 and 5,0. the solutions are faintly colored.
EXAMPLE IV
Stabilization of paracetamol in solution by oxygen removal through nitrogen bubbling
4.2 Diluted solution
AP/P/ 9 8 / 0 1 2 2 3
Solution Tested
AP 00957
Quantity
Ingredient Solution without nitrogen bubbling solution subjected to nitrogen bubbling
Paracetamol 0.008 g 0.008 g
Sodium chloride 0.008 g 0.008 g
Disodium phosphate dihydrate 0.001 g 0.001 g
5% Citric acid q.s.f. pH 6.0 q.s.f. pH 6.0
Nitrogen none q.s.f. purging and filling
Water for injection q.s.f. 1000 ml q.s.f. 1000 ml
The diluted aqueous solution containing paracetamol is adjusted to pH 6,0 by means of a citric acid solution.
Vials that had been filled under a nitrogen atmosphere by dispensing ml of such solutions, were tightly stoppered and capped and then stored inside an incubator at 98°C for 15 hours.
The percentage of secondary peaks in relation to the main peak of paracetamol was measured by liquid chromatography, so was the pink color io strength by reading the solution absorbance by absorbance spectrophotometry at a peak absorption wavelength, that is 500 nm.
Results
AP/P/ 9 8 / 0 1 2 2 3
Solution tested Secondary peaks in % of paracetamol main peak Solution absorbance at 500 nm
Solution packed without nitrogen atmosphere 1.57 0.036
Solution packed under nitrogen atmosphere 0.44 0.016
AP 00957
The pink color of the solution packed under nitrogen atmosphere is considerably fainter than that observed for the solution obtained after sterilization under nitrogen of the solution packed without nitrogen.
EXAMPLE V
Stabilizing solutions of paracetamol by adding free radical antagonists
5,1 Concentrated solution
Ingredient Quantity
Paracetamol 0.160 g
Propylene-glycol 0.270 ml
PEG 400 0.360 ml
Hydrochloric acid 1N or NaOH 1N q.s.f. pH 6.0
Free radical scavenger (see quantitative results) q.s.f. (see quantitative results)
Nitrogen q.s.f. purging and filling
Water for injection q.s.f. 1000 ml
io The solutions thus prepared are divided in 10 ml capacity vials, stoppered with a Bromobutyl stopper and capped with an aluminium cap. After autoclaving at 121°C for 20 minutes, the vials were stored for 48 hours, either in the presence of actinic light at 5500°K at room temperature or at 70°C in the dark. The preparation was examined for any change in color.
AP/P/ 9 8 / 0 1 2 2 3
Results
AP 00957
Free radical scavenger Concentration Appearance of the solution upon exposure to light Color intensity Appearance of solution at 70°C Color intensity
No scavenger - pink (+) pink (++)
Sodium disulfite 0.295 mg/ml colorless colorless
Sodium ascorbate 1.0 mg/ml yellow (+) yellow (+)
Reduced glutathion 1 mg/ml colorless colorless
Reduced glutathion 8 mg/ml colorless colorless
Cystein hydrochloride 1 mg/ml cloudy cloudy
cc-monothioglycerol 1 mg/ml colorless colorless
Dithiothreitol 1 mg/ml colorless colorless
Mannitol 50 mg/ml colorless colorless
5,2 Dilute solution 5 Solutions tested
AP/P/ 9 8 / 0 1 2 2 3
Ingredient Quantity
Formulation A Formulation B Formulation C
Paracetamol 0.008 g 0.01 g 0.0125 g
Sodium chloride 0.008 g 0.008 g 0.00486 g
Disodium phosphate dihydrate or sodium acetate 0.001 g 0.001 g 0.00125 g
Hydrochloric acid q.s. ph 6.0 q.s. pH 6.0 q.s. pH 5.5
C.R.L. q.s. (see quantitative results)
Nitrogen q.s.f. purging and filling
Water q.s.f. 1000 ml
The solutions thus prepared were divided in 10 ml, 100 ml or 80 ml capacity vials, stoppered with a Bromobutyl stopper and capped with an io aluminium cap. The preparation was examined for any pink color development
AP 00957
After autoclaving at 121 °C for 20 minutes, the vials were stored for 48 hours, either in the presence of actinic light at 5500°K at room temperature or at 70°C in the dark (formula A).
After autoclaving at 124°C for 7 minutes, the vials were stored for 48 5 hours at room temperature in the dark (formulation B and C). The preparation was examined for any pink shift and the paracetamol as well as CRL were measured where a thiol derivative was used.
Results (CRL = free radical scavenger)
C.R.L used Concentration Solution appearance upon exposure to light Solution appearance at 70°C
color strength color strength
No C.R.L - pink (+) pink (++)
Thiourea 0.5 mg/ml colorless colorless
Dithiothreitol 1 mg/ml colorless colorless
a-monothioglycerol 1 mg/ml colorless colorless
gluthathion 1 mg/ml colorless colorless
Sodium ascorbate 0.2 mg/ml pink (+) pink (+)
0.4 mg/ml colorless yellow (+)
0.6 mg/ml pink (+) yellow (+)
1.0 mg/ml colorless yellow (+)
Cystein hydrochloride 0.05 mg/ml colorless colorless
0.1 mg/ml colorless colorless
0.25 mg/ml colorless colorless
0.5 mg/ml colorless colorless
0.75 mg/ml colorless colorless
1 mg/ml colorless colorless
2 mg/ml colorless colorless
5 mg/ml colorless colorless
AP/P/ 9 8 / 0 1 2 2 3 io
AP 00957
C.R.L used Concentration Solution appearance Dosages (in % of theoretical value)
color strength C.R.L. paracetamol
Cystein hydrochloride monohydrate 0.2 mg/ml colorless 80% 99.2%
Cystein hydrochloride monohydrate 0.5 mg/ml colorless 95% 99.6%
N- acety Icy stein 0.2 mg/ml colorless 88% 99.2%
Mannitol 20 mg/ml colorless
Mannitol 40 mg/ml colorless
Mannitol 50 mg/ml colorless
Glucose 50 mg/ml colorless
EXAMPLE VI
Stabilization of solutions of paracetamol containing a morphinic 5 compound by addition of a free radical scavenger
6,1 Concentrated solution
Solutions tested
AP/P/ 9 8 / 0 1 2 2 3
Ingredient Quantity
Paracetamol 0.160 g
Codein phosphate 0.008 g
Propylene-glycol 0.270 ml
PEG 400 0.360 ml
Hydrochloric acid 1N q.s. q.s. pH 6.0
Free radical scavenger q.s. (see quantitative results)
Water for injection q.s.f. 1000 ml
AP 00957
The solutions thus prepared were divided in 10 ml capacity vials, stoppered with a Bromobutyl stopper and capped with a removable aluminium cap. After autoclaving at 121°C for 20 minutes, the vials were stored for 48 hours either under actinic light at 5500 °K at room temperature, or at 70°C in the dark. The preparation was inspected for any change in color.
Results
Free radical scavenger Concentration Solution apperance upon exposure to light Solution apperance at 70°C
color strength color strength
No free radical scavenger pink (+) pink (++)
Sodium disulfite 0.295 mg/ml yellow (+) yellow (++)
Sodium ascorbate 1.0 mg/ml yellow (++) yellow (+++)
reduced glutathion 1 mg/ml yellow (+) amber yellow (+++)
8 mg/ml colorless yellow (++)
16 mg/ml colorless yellow (+)
Dithiothreitol 1 mg/ml violet pink (+++) violet pink (++++)
Sodium hypophosphite 5 mg/ml pink (+) pink (++)
AP/P/ 9 8 / 0 1 2 2 3 io 6,2 Dilute solutions
Solutions tested
AP 00957
Ingredient Quantity
Paracetamol 0.008 g
Codein phosphate 0.0004 g
Sodium chloride 0.008 g
Disodium phosphate dihydrate 0.0015 g
Hydrochloric acid q.s.f. pH 6,0
Free radical scavenger q.s. (see results)
Nitrogen q.s.f. purging and filling
Water for injection q.s.f. 1000 ml
The solutions thus prepared were divided in 10 ml capacity vials, stoppered with a Bromobutyl stopper and capped with an aluminium cap. After autoclaving at 121 °C for 20 minutes, the vials were stored for 48 hours, either under actinic light at 5500°C at room temperature, or at 70°C in the dark. The preparation was examined for any change in color.
For the solution not containing any free radical scavenger and for the solution containing 0.5 mg/ml of cystein hydrochloride as free radical io antagonist, paracetamol as well as codein are measured by high performance liquid chromatography, immediately after autoclaving, in comparison with identical solutions not subjected to autoclaving.
AP/P/ 9 8 / 0 1 2 2 3
Appearence scoring of the solutions
AP 00957
Free radical scavenger Concentration Solution appearance upon exposure to light Solution appearance at 70°C
color strength color strength
No free radical scavenger pink (+) pink (+)
Sodium disulfite 0.295 mg/ml colorless colorless
Dithiothreitol 0.5 mg/ml colorless colorless
Monothioglycerol 0.5 mg/ml grey grey
Reduced glutathion 2.0 mg/ml colorless colorless
N-acetylcystein 2.0 mg/ml grey (+) grey (+)
Cystein hydrochloride 0.05 mg/ml colorless pink (+)
0.1 mg/ml colorless colorless
0.25 mg/ml colorless colorless
0.5 mg/ml colorless colorless
0.75 mg/ml colorless colorless
1.0 mg/ml colorless colorless
2.0 mg/ml colorless colorless
5.0 mg/ml colorless colorless
AP/P/ 9 8 / 0 1 2 2 3
Assay results of paracetamol and codein
Solution tested Ingredient assayed non sterilized solution after sterilization
Solutions with no free radical scavenger added paracetamol codein 0.0078 g/ml 0.00043 g/ml 0.0077 g/ml 0.00042 g/ml
Solution containing 0,5 mg/ml of cystein hydrochloride paracetamol codein 0.0082 g/ml 0.00042 g/ml 0.0081 g/ml 0.00042 g/ml
Αζ λ'*’?·. ζ* >» -ν.
Mr' 0 0 9 5 7
There is noted the lack of color development one one hand and excellent preservation of the active ingredients after heat treatment sterilization on the other hand.
EXAMPLE VII
Biological tolerance to the preparation
7.1 Hematological tolerance
Tested solutions
Ingredient Quantity
Paracetamol 0.160 g
Propylene-glycol 0.270 ml
PEG 400 0.360 ml
Nitrogen q.s.f. purging and filling
Water for injection q.s.f. 1000 ml
The solution pH was not adjusted. The apparent pH is 7.6, corresponding to an actual pH of 6.5.
Whole human blood is incubated with the solution under study, in equal proportions by volume. 2 ml were drawn at 10 minutes intervals and centrifuged for 5 minutes at 5000 rpm. 100 pi of the supernatant were diluted in 1 ml of distilled water. The absorbance of this solution was determined against a water blank at 540 nm, peak absorption wavelength of hemoglobin.
The study was run in comparison with a negative control (physiological saline) and a positive control (pure water for injection).
Results
The absorbances of the individual solutions after different incubation periods are provided in the following table :
AP/P/ 9 8 / 0 1 2 2 3
AP 00957
Solution TO 10 min 20 min 30 min 40 min 50 min 60 min
Water p.p.i 2.23 2.52 2.30 2.37 2.38 2.33 2.36
Physiological saline 0.04 0.05 0.05 0.05 0.04 0.05 0.04
Sol. Tested 0.09 0.19 0.27 0.25 0.24 0.24 0.25
No hemolysis was detected.
7.2 Muscular tolerance
Solution tested
Ingredient Quantity
Paracetamol 0.160 g
Propylene-glycol 0.270 ml
PEG 400 0.360 ml
Nitrogen q.s.f. purging and filling
Water for injection q.s.f. 1000 ml
The pH of this solution was not adjusted. Apparent pH is equal to 7,6. Sprague-Dawley rats, weighing between 260 g and 450 g were anesthesized with an i.p. injection of ethyl carbamate (2 ml/kg of a 50% io aqueous solution). The extensor digitorum longus muscle was dissected from the right or left hind leg, and placed in buffer medium having the following composition :
AP/P/ 9 8 0 12 2 3
Ingredient Quantity
Sodium chloride 6.8 g
Potassium chloride 0.4 g
Dextrose 1.0 g
Sodium bicarbonate 2.2 g
Phenol red (sodium salt) 0.005 g
Distilled water q.s.f. 1 liter
Hydrochloric acid 1N q.s.f. pH 7.4
AP 00957
The muscle is transiently fixed to a board and maintained in position by tendons. The test product was injected in an amount of 15 pi by means of a 25 μΙ-capacity Hamilton seringe n° 702. The muscle is then placed over a grit and immersed in the buffer solution kept at 37°C with carbogen bubbling throughout the incubation period. At 30 minutes intervals, the muscles were introduced in a tube containing fresh buffer at 37°C. The procedure was repeated 4 times. The buffer solution hence incubated is assayed for creatine kinase activity.
The study was run in parallel with : io - muscle alone not subjected to injection (blank)
- needle alone (introducing the needle without product injection)
- physiological saline
- Triton X-100 solution (negative controls)
- solution 20
- solution 20 + paracetamol 160 mg/ml.
Creatine kinase was measured using a Hitachi 704 model analyzer in conjunction with a reagent kit sold under tradename high performance Enzyline CK NAC 10 (Biomerieux).
Results
The creatine kinase activity (IU/I) of the individual solutions after variable incubation periods are provided in the table given hereinafter :
AP/?/ 9 8/01223
Solution tested 30 min 60 min 90 min 120 min Total
Muscle alone 23 + 6 24 + 12 15 + 7 13 + 5 75
Needle alone 35 + 6 33 + 10 20 + 4 18 + 7 106
Physiological saline 30 + 6 10 + 12 17 + 5 23 + 4 100
T riton-X 1802 + 2114 1716 + 978 155 + 89 289 + 251 14962
SOution^ 20 (excipients) 71 + 24 89 + 40 39 + 27 62 + 39 261
Solution 20 + paracetamol 141 +40 150 + 60 68 + 63 34 + 24 393
AP 00957
No necrosis signs were recorded using the composition according to the invention as no significant difference between the results of test and excipient solutions was noted.

Claims (26)

1. Paracetamol-based, stable, liquid formulations in an aqueous solvent, wherein the aqueous solvent is a mixture containing water, a buffering agent, and at least one member of the group consisting of a free radical antagonist and a free radicalscavenger.
2. Paracetamol-based, stable, liquid formulations according to claim 1, wherein the aqueous solvent is deoxygenated by bubbling a water-insoluble inert gas.
3. Paracetamol-based, stable, liquid formulations according to claim 1, wherein the pH of the aqueous solvent is adjusted by means of the buffering agent, in the range of 4 to 8.
4. Paracetamol-based, stable, liquid formulations according to claim 2, wherein the buffering agent yields a pH of approximately 6.0.
5. Paracetamol-based, stable, liquid formulations according to claim 1, wherein the free radical-scavenger is chosen among ascorbic acid derivatives, organic compounds bearing at least one thiol functional group, and polyhydric compounds.
6. Paracetamol-based, stable, liquid formulations according to claim 5, wherein the ascorbic acid derivatives are chosen from the group of D-ascorbic acid, L-ascorbic acid, alkali metal ascorbates, alkaline earth metal ascorbates and ascorbic acid esters that are soluble in aqueous medium.
7. Paracetamol-based, stable, liquid formulations according to claim 5, wherein the organic compound bearing the thiol functional group is chosen
98/01223
AP 00957 among the compounds of the aliphatic or alicyclic series, bearing one or a number of thiol functional groups.
8. Stable paracetemol-based liquid formulations according to claim 5, wherein the compound bearing the thiol functional group is. chosen from the group of thioglycolic acid, thiolactic acid, dithiothreitol, reduced glutathion, thiourea, α-thioglycerol, cystein, acetylcystein and mercaptoethane sulfonic acid.
9. Paracetamol-based, stable, liquid formulations according to claim 5, wherein the polyhydric compound is an aliphatic polyhydric alcohol containing from 2 to 10 carbon atoms.
10. Stable, paracetamol-based, liquid formulations, according to claim 5, wherein the polyhydric compound is a sugar or a cyclic or straight chainglucitol, having from 2 to 10 carbon atoms.
11. Stable, paracetamol-based, liquid formulations, according to claim 10, wherein the polyhydric compound is selected among mannitol, sorbitol, inositol and glucose.
12. Paracetamol-based, stable, liquid formulations according to claim 10, wherein the polyhydric compound is glycerol.
13. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 12, further comprising at least one complexing agent.
14. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, wherein the paracetamol concentration ranges from 2 mg to 50 mg/ml as for diluted solutions.
AP/P/ 9 8 / 0 1 2 2 3
AP 00957
15. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, wherein the paracetamol concentration ranges from 60 mg to 350 mg/ml as for concentrated solutions.
16. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, wherein an appropriate quantity of isotonizing agent is added to the preparation.
17. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, wherein solutions intended for parenteral administration are sterilized by heat treatment.
CSl
18. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, further comprising a central nervous system-acting analgesic c?
such as for example a morphinic analgesic.
co
Cf>
19. Paracetamol-based, stable, liquid formulations according to claim 18, n, wherein the morphinic analgesic is a morphinic compound of natural, semi- ΐζsynthetic or synthetic origin, a phenylpiperidine compound, a nipecotic acid compound, a phenylcyclohexanol compound ora phenylazepine compound.
20. Paracetamol-based, stable, liquid formulations according to claim 19, wherein the morphinic analgesic is present in a quantity ranging from 0,05 to 5% of paracetamol in case of morphine and from 0,2 to 2,5% in case of codeine.
21. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, further comprising an anti-inflammatory agent such as that of the phenylacetic acid type.
AP 00957
22. Paracetamol-based, stable, liquid formulations according to claim 21, wherein the anti-inflammatory agent is ketoprofen.
23. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, further comprising an antiemetic agent.
24. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, further comprising an antiepileptic agent.
25. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, further comprising a corticosteroid.
26. Paracetamol-based, stable, liquid formulations according to anyone of claims 1 to 13, further comprising a tricyclic antidepressant.
APAP/P/1998/001223A 1996-08-05 1997-08-05 Novel stable liquid paracetamol compositions, and method for preparing same. AP957A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9609858A FR2751875B1 (en) 1996-08-05 1996-08-05 NOVEL STABLE LIQUID FORMULATIONS BASED ON PARACETAMOL AND THEIR METHOD OF PREPARATION

Publications (2)

Publication Number Publication Date
AP9801223A0 AP9801223A0 (en) 1998-06-30
AP957A true AP957A (en) 2001-04-12

Family

ID=9494820

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001223A AP957A (en) 1996-08-05 1997-08-05 Novel stable liquid paracetamol compositions, and method for preparing same.

Country Status (23)

Country Link
US (1) US6028222A (en)
EP (1) EP0858329B1 (en)
JP (2) JP5060681B2 (en)
KR (1) KR100521235B1 (en)
CN (1) CN1133426C (en)
AP (1) AP957A (en)
AT (1) ATE241972T1 (en)
AU (1) AU742576B2 (en)
BR (1) BR9702362A (en)
CA (1) CA2233924C (en)
CZ (1) CZ298427B6 (en)
DE (1) DE69722580T2 (en)
DK (1) DK0858329T3 (en)
ES (1) ES2201316T3 (en)
FR (1) FR2751875B1 (en)
HU (1) HU226117B1 (en)
MX (1) MX9802734A (en)
NZ (1) NZ330136A (en)
OA (1) OA10678A (en)
PL (1) PL193104B1 (en)
PT (1) PT858329E (en)
RU (1) RU2192249C2 (en)
WO (1) WO1998005314A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
FR2779061B1 (en) * 1998-04-14 2004-08-20 Pharmatop NOVEL METHOD FOR STABILIZING PHENOLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS THEREFROM
IT1301976B1 (en) 1998-07-31 2000-07-20 Angelini Ricerche Spa INJECTABLE PHARMACEUTICAL COMPOSITION BASED ON PARACETAMOL
SI1181197T1 (en) * 1999-05-28 2004-04-30 Novartis Ag Package for a pharmaceutical product and method of sterilising the package
DE19932157A1 (en) * 1999-07-13 2001-01-18 Pharmasol Gmbh Process for the gentle production of ultra-fine microparticles and nanoparticles
US6334859B1 (en) 1999-07-26 2002-01-01 Zuli Holdings Ltd. Subcutaneous apparatus and subcutaneous method for treating bodily tissues with electricity or medicaments
IT1313579B1 (en) * 1999-07-30 2002-09-09 Acraf PARACETAMOL-BASED LIQUID PHARMACEUTICAL COMPOSITION.
GB0006897D0 (en) * 2000-03-23 2000-05-10 Smithkline Beecham Plc Medicaments
AU2006203741B2 (en) * 2000-06-06 2009-11-05 Scr Pharmatop Method for obtaining aqueous formulations with active principles susceptible to oxidation and the aqueous solutions thus obtained
FR2809619B1 (en) * 2000-06-06 2004-09-24 Pharmatop NOVEL AQUEOUS FORMULATIONS OF OXIDATION-SENSITIVE ACTIVE INGREDIENTS AND PROCESS FOR OBTAINING THEM
DE10112325A1 (en) * 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Storage stable ready-to-use infusion solutions of paracetamol
ITMI20012135A1 (en) 2001-10-16 2003-04-16 Bioren S A INJECTABLE SOLUTIONS READY TO USE PARACETAMOL
HUP0402549A3 (en) * 2001-12-18 2006-01-30 Tseti Ioulia Parenteral composition of paracetamol
FR2851164B1 (en) * 2003-02-14 2005-04-22 Xuan Tho Nguyen INFLATABLE LIQUID FORMULATION OF PARACETAMOL
BG65674B1 (en) * 2003-07-10 2009-06-30 Нихфи Ад Liquid form of combined medicamentous preparation for the treatment of colds and flue diseases
ES2336034T3 (en) * 2004-03-10 2010-04-07 Shimoda Biotech (Pty) Ltd STABLE INJECTABLE DICLOFENAC COMPOSITIONS.
US20060205752A1 (en) * 2005-03-14 2006-09-14 Keith Whitehead Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid
DE102005037653A1 (en) * 2005-08-05 2007-02-15 Theraselect Gmbh Stable, liquid formulation of paracetamol
US20070098790A1 (en) * 2005-10-31 2007-05-03 David Jiang Nutritional supplement for the enhancement of the health of the liver
FR2894154B1 (en) * 2005-12-06 2008-03-14 Pharmatop Scr NOVEL METHOD FOR STABILIZING OXIDATION - SENSITIVE MINERAL OR ORGANIC SUBSTANCES.
KR20150050595A (en) * 2006-03-28 2015-05-08 자블린 파머슈티칼스 인코포레이티드 Formulations of low dose diclofenac and beta-cyclodextrin
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
CA2628806C (en) 2006-07-18 2012-08-21 Genfarma Laboratorio S.L. Injectable liquid paracetamol formulation
EP1992334A1 (en) * 2007-05-08 2008-11-19 Docpharma NV/SA Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation
WO2009047634A2 (en) * 2007-06-18 2009-04-16 Combino Pharm, S.L. Aqueous formulations of acetaminophen for injection
AR067047A1 (en) * 2007-06-18 2009-09-30 Combino Pharm Sl ACETAMINOFEN WATERY FORMULATIONS FOR INJECTION.
US9399012B2 (en) * 2007-11-13 2016-07-26 Mallinckrodt Ip Reduced dose intravenous acetaminophen
US20110015273A1 (en) * 2008-01-17 2011-01-20 Rajnarayana Kandhagatla Stable pharmaceutical aqueous compositions
FR2926992B1 (en) * 2008-02-06 2011-01-14 Moly Pharma FORMULATION OF AN INJECTABLE PARACETAMOL SOLUTION, PROCESS FOR PREPARING AND PACKAGING SUCH A SOLUTION AND DEVICE FOR CONDITIONING SUCH A SOLUTION
WO2009157010A1 (en) * 2008-06-25 2009-12-30 Akums Drugs And Pharmaceuticals Limited An intravenous drug delivery system
WO2009157009A1 (en) * 2008-06-25 2009-12-30 Akums Drugs And Pharmaceuticals Limited An intravenous drug delivery system
EP2243477A1 (en) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol for parenteral application
WO2011008976A1 (en) * 2009-07-15 2011-01-20 Leland Stanford, The Board Of Trustees Of The Junior University N-acetyl cysteine compositions and methods to improved the therapeutic efficacy of acetaminophen
SI2277546T1 (en) * 2009-07-23 2015-09-30 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
EP2464332B1 (en) 2009-08-13 2016-03-02 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
US8404748B2 (en) * 2009-08-13 2013-03-26 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
FR2950533B1 (en) * 2009-09-28 2012-01-13 Maco Pharma Sa LIQUID FORMULATION, STABLE, READY TO USE KETOPROFEN
EP2308463A1 (en) * 2009-10-12 2011-04-13 EMP Pharma GmbH Aqueous acetaminophen compositions and method of preparation
CN102711726A (en) 2009-12-10 2012-10-03 特克尼梅德医疗技术股份公司 Method and composition for preparing stable liquid formulations of paracetamol
RU2446799C2 (en) * 2010-01-22 2012-04-10 Анатолий Брониславович Гаврилов Antioxidant composition
US20110207824A1 (en) * 2010-02-25 2011-08-25 Moly Pharma Formulation of an injectable paracetamol solution, method for preparing and packaging such a solution and device for packaging such a solution
PT2377516E (en) 2010-04-14 2012-07-02 Braun Melsungen Ag Acetaminophen composition
GR1007315B (en) * 2010-04-19 2011-06-14 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Abee, A parenteral-administration tramadol-and-paracetamol liquid composition
SI2389923T1 (en) * 2010-05-19 2013-06-28 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
EP2389931A1 (en) 2010-05-21 2011-11-30 Raw Materials Internatinal LLC Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
CN102958519B (en) * 2010-06-30 2016-01-13 特罗伊卡药品有限公司 Pharmaceutical composition comprising acetaminophen and preparation method thereof
KR20130132496A (en) * 2010-12-09 2013-12-04 마루이시세이야쿠가부시키가이샤 Stabilizer of acetaminophen
CN102600068A (en) * 2011-01-24 2012-07-25 联康药业克雷恩特塞提斯制药实验室有限责任公司 Stable ready-to-use paracetamol preparation capable of being injected
AU2011200289B2 (en) * 2011-01-24 2016-10-13 Ioulia Tseti Stable ready to use injectable paracetamol formulation
US9089477B2 (en) 2011-02-10 2015-07-28 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
ES2414557B1 (en) 2012-01-16 2014-06-10 Novocat Farma, S.A. Aqueous composition of paracetamol for injection
ITMI20121154A1 (en) 2012-06-29 2013-12-30 Sint Sa INJECTABLE ACETAMINOFENE SOLUTION FOR SPINAL ADMINISTRATION
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
ZA201300398B (en) 2012-11-27 2013-09-25 Genfarma Laboratories S L Injectable liquid formulation of the combination of tramadol and paracetamol
US10272097B2 (en) 2013-12-24 2019-04-30 Virginia Commonwealth University Uses of oxygenated cholesterol sulfates (OCS)
BR102014005885B1 (en) 2014-03-13 2021-04-13 Biotec Biológica Indústria Farmacêutica Ltda E.P.P STABLE INJECTABLE LIQUID PHARMACEUTICAL FORMULATION OF PARACETAMOL IN PLASTIC BAG READY FOR USE
US20170202793A1 (en) 2014-07-25 2017-07-20 Terumo Kabushiki Kaisha Packaged acetaminophen injection solution preparation
SG11201704435PA (en) * 2014-12-20 2017-06-29 Troikaa Pharmaceuticals Ltd Injectable formulations of paracetamol
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
MX2018009497A (en) * 2016-02-05 2019-05-06 Innopharma Inc Process of manufacturing a stable, ready to use infusion bag for an oxidation sensitive formulation.
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
MX2019003257A (en) * 2016-09-23 2019-06-10 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol.
KR101942568B1 (en) * 2017-01-24 2019-01-30 주식회사 우성제약 Injectable composition containing acetaminophen
CA3051467C (en) 2017-01-30 2022-11-29 Nevakar, Inc Norepinephrine compositions and methods therefor
WO2018192664A1 (en) * 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
RU2737852C2 (en) * 2017-12-28 2020-12-03 Беккер Герман Петрович Method of producing a drug based on oligopeptide alloferon-1, having an antiviral and immunomodulating effect, and prolonged storage medicinal product obtained with its help
CN115385818B (en) * 2022-09-01 2023-09-29 江苏海洋大学 Paracetamol impurity and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314989A (en) * 1980-05-07 1982-02-09 Rosen Gerald M Methionine sulfoxide amflioration of acetaminophen toxicity
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO82841A2 (en) * 1981-08-04 1983-11-01 Intreprinderea De Medicamente "Biofarm",Ro SUSPENSION WITH PARACETAMOL
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
FR2646773B1 (en) * 1989-05-12 1994-05-13 Chauvin Sa Laboratoire PHARMACEUTICAL COMPOSITION BASED ON PARACETAMOL
JPH0714872B2 (en) * 1990-02-06 1995-02-22 昭和薬品化工株式会社 Syrup composition
JPH0672897A (en) * 1991-03-27 1994-03-15 Cullim & Assoc Inc Composition for reducing various unplesant symptoms before and during menstruation
US5252313A (en) * 1991-12-20 1993-10-12 Colgate-Palmolive Company Visually clear gel dentifrice
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
EP0620001A1 (en) * 1993-04-16 1994-10-19 McNEIL-PPC, INC. Aqueous pharmaceutical suspension and process for preparation thereof
DE4327462A1 (en) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer N-Acetyl-p-aminophenol derivatives for controlling pain
JPH07206689A (en) * 1994-01-21 1995-08-08 Barnett Lab Ltd Curing composition and use of this composition for curing crapulence
PL315635A1 (en) * 1994-01-24 1996-11-25 Procter & Gamble Method of solubilising hardly pharmaceutically active substances
US5510389A (en) * 1994-03-02 1996-04-23 The Procter & Gamble Company Concentrated acetaminophen solution compositions
JPH09286724A (en) * 1996-04-19 1997-11-04 Takeda Chem Ind Ltd Liquid stablizer for oral administration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314989A (en) * 1980-05-07 1982-02-09 Rosen Gerald M Methionine sulfoxide amflioration of acetaminophen toxicity
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds

Also Published As

Publication number Publication date
AU742576B2 (en) 2002-01-10
WO1998005314A1 (en) 1998-02-12
CN1204960A (en) 1999-01-13
EP0858329B1 (en) 2003-06-04
HUP9901893A2 (en) 1999-09-28
PT858329E (en) 2003-09-30
ATE241972T1 (en) 2003-06-15
OA10678A (en) 2002-11-20
HU226117B1 (en) 2008-04-28
ES2201316T3 (en) 2004-03-16
AP9801223A0 (en) 1998-06-30
HUP9901893A3 (en) 2000-06-28
DE69722580D1 (en) 2003-07-10
DE69722580T2 (en) 2004-04-29
CN1133426C (en) 2004-01-07
FR2751875B1 (en) 1998-12-24
DK0858329T3 (en) 2003-09-29
KR19990063978A (en) 1999-07-26
PL193104B1 (en) 2007-01-31
US6028222A (en) 2000-02-22
JP5122604B2 (en) 2013-01-16
RU2192249C2 (en) 2002-11-10
JP2010163462A (en) 2010-07-29
MX9802734A (en) 1998-11-30
KR100521235B1 (en) 2006-01-27
CZ298427B6 (en) 2007-10-03
NZ330136A (en) 2000-03-27
PL326069A1 (en) 1998-08-17
CA2233924A1 (en) 1998-02-12
AU3945197A (en) 1998-02-25
JPH11514013A (en) 1999-11-30
FR2751875A1 (en) 1998-02-06
CZ104898A3 (en) 1998-09-16
EP0858329A1 (en) 1998-08-19
JP5060681B2 (en) 2012-10-31
BR9702362A (en) 1999-12-28
CA2233924C (en) 2012-08-21

Similar Documents

Publication Publication Date Title
AP957A (en) Novel stable liquid paracetamol compositions, and method for preparing same.
JP5847643B2 (en) Pharmaceutical formulations containing methylnaltrexone
TWI342212B (en) Liquid pharmaceutical formulations of palonosetron
EA029478B1 (en) Stable solutions of combined active pharmaceutical ingredients for oral administration
CN114796105B (en) Stable AST-3424 injection preparation and preparation method thereof
JP2003521518A (en) Pharmaceutical composition comprising pemetrex together with monothioglycerol, L-cysteine or thioglycolic acid
JP3043381B2 (en) Folic acid and leucovorin salts which are stable and can be used as injections and a method for producing the same
UA104381C2 (en) Stable composition of paracetamolum prepared to application for injections
EP1465663A1 (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
AU2002342826A1 (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
JPWO2008023807A1 (en) Stabilized pharmaceutical composition
CA3045794A1 (en) Levothyroxine liquid formulations
WO2020011753A1 (en) Compositions for therapeutic uses containing 5-htp and carbidopa
IE50512B1 (en) Pharmaceutical injectable composition and two-pack container for said composition
US20240033215A1 (en) Injectable formulation with enhanced stability containing dexibuprofen and arginin and their medicine vessel for injection
JPH04346926A (en) Syrup agent